Sensei biotherapeutics reports third quarter 2022 financial results and recent business highlights

- recent sns-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile -

SNSE Ratings Summary

SNSE Quant Ranking